Zoetis appoints Iris Knobloch to board, expanding it to 13 members
The animal health company named Knobloch a director effective December 1, 2026, days after declaring its fourth-quarter dividend of $0.53 per share.
SEC filing (2)
Latest
Tuesday, October 13
Friday, October 9
FDA approves efficacy supplement for Amgen's Repatha
The FDA approved supplement 47 for Amgen's cholesterol drug Repatha on October 9, 2026, according to agency records.
Drugs@FDA
Hepion Pharmaceuticals acquires Gravitas Life Sciences, installs new CEO
Hepion closed a deal for Gravitas Life Sciences on October 6, 2026, and named Sireesh Appajosyula as CEO three days later.
SEC filing
Par Health recalls two lots of Brevital Sodium over particulate matter
The company is pulling two lots of the 500 mg/vial CIV injectable from hospital-level stock after cellulose particles were found in the product.
FDA
FDA approves Bracco's Isovue Readi oral contrast solution
The agency cleared the new formulation under a standard review, with four strengths of iopamidol listed in the application.
Drugs@FDA
FDA approves efficacy supplement for Eli Lilly's Olumiant
The agency's drug approvals database lists a new supplemental approval for baricitinib, with a status date of October 9, 2026.
Drugs@FDA
Genentech lists Phase Ib KRAS G12D trial; Roche-sponsored DLBCL study shows update
Incyte registers Phase 2 FIGHT-214 trial of pemigatinib in cholangiocarcinoma
Pfizer registers real-world observational study of marstacimab in hemophilia A and B patients
VistaGen expands severance plan terms for executives beyond change-in-control events
The company's board amended its executive severance plan on October 7, 2026, broadening when employees qualify for benefits after involuntary termination.
SEC filing
Beyond Air preannounces $2.3 million revenue, reaffirms 2026 and 2027 guidance
The company said LungFit PH sales rose on commercial execution gains while its second-generation system stays under FDA review.
SEC filing (2)
Arrowhead's two Phase 3 plozasiran SHTG trials both show completed status this week
Arcus Biosciences completes Phase 1/1b trial of AB801 in advanced malignancies
BioRestorative Therapies appoints Donald J. Currie to board of directors
Currie fills the Class I director seat left vacant by Katharyn Field's resignation, effective immediately as of October 7, 2026.
SEC filing
Jazz Pharmaceuticals discloses retirement plan for chief commercial officer
Samantha Pearce told the company on October 6, 2026 that she will step down as Chief Commercial Officer no later than June 30, 2027, or sooner if a successor is named.
SEC filing
Bambusa Therapeutics files for IPO, discloses bispecific antibody data
The clinical-stage biopharmaceutical company filed an S-1 with the SEC on October 9, 2026 to list on Nasdaq under the ticker "BBTX."
SEC filing (2)
Sunshine Biopharma prices, then closes $6.0 million Nasdaq offering
The pharmaceutical company priced a reworked unit offering at $0.55 per share on October 8 and closed the deal the next day through placement agent Aegis Capital Corp.
SEC filing (3)
Novo Nordisk registers Phase 3 cardiovascular outcomes trial for zenagamtide, acronym AMBIENCE
Iovance registers Phase 2 lifileucel trial in advanced soft tissue sarcoma, 'SARATOGA'
Takeda posts Phase 2 TAK-101 celiac results; registers two observational studies
Moderna posts Phase 2 mRNA-1083 results; VX-522 completes; new Phase 3b/4 study registers
Vogenx names board member Richard Gorman as Chief Commercial Officer
Gorman will resign from the Vogenx board effective October 12, 2026 as he moves into the newly created commercial role.
SEC filing
Moleculin shareholders approve reverse split authority, reject supermajority repeal
At its October 9, 2026 annual meeting, Moleculin Biotech investors authorized the board to execute a reverse stock split of up to 1-for-20 and expanded the equity incentive plan.
SEC filing
Atossa executes CVR agreement tied to future priority review voucher value
Shareholders of record October 19, 2026 get one stapled CVR per share, entitling holders to 25% of net proceeds from Atossa's first qualifying voucher, capped at $50 million.
SEC filing
Viking registers two Phase 3 trials for oral VK2735 in weight management
Lilly advances obesity and inflammation pipeline with new Phase 1 trials, Phase 2 updates
Vaxcyte closes $575 million convertible notes offering and stock sale
Vaxcyte completed concurrent equity and debt offerings on October 9, 2026, raising roughly $1.1 billion in combined net proceeds.
SEC filing
Quantum Cyber files $100 million at-the-market stock offering
The former Mainz Biomed, now focused on AI and quantum tech for drones, set terms with Titan Partners for shares sold as needed on Nasdaq.
SEC filing
Karyopharm posts results for selinexor trial testing hepatic impairment dosing, combinations
Quantum Cyber N.V. launches $100 million at-the-market share offering
The company entered a sales agreement with Titan Partners Securities to sell ordinary shares from time to time under an existing shelf registration.
SEC filing
Myriad Genetics details separation terms for former chief commercial officer
A filing shows Brian Donnelly's severance package totals over $1.3 million in cash plus accelerated equity vesting.
SEC filing
BioStem files Form D for $3 million offering tied to September private placement
The regenerative medicine company disclosed a Form D exempt securities notice as its S-1 resale registration and going concern disclosures remain pending.
SEC filing (3)
Vertex registers Phase 1 mass balance study of VX-407 in healthy volunteers
GT Biopharma files S-1 to register 13.5 million shares for resale
The clinical stage biopharmaceutical company registered shares tied to September 2026 and May 2025 private placements and a completed reverse stock split.
SEC filing
CTX-471 trial terminated after combo arm misses efficacy; two device trials await start
GSK discloses FDA hold on infant pneumococcal vaccine study; posts two Phase 3/4 results
Merck registers Phase 2b trial of tulisokibart for noninfectious uveitis
Novartis registers new Phase 2 NIO752 tauopathy trial; Egaten results, six studies update
bioAffinity closes $4 million offering, adds pre-funded warrants to prior deal
bioAffinity Technologies closed its registered direct offering and private placement on October 9, 2026, finalizing terms disclosed a day earlier alongside its ATM suspension.
SEC filing (3)
Quince Therapeutics becomes IRulya Therapeutics, names new CEO, moves to Nasdaq ticker IRLA
The company completed its name change October 9, 2026, installed Brigette Roberts as CEO, and said its $116 million cash balance should fund operations into late 2028.
SEC filing (2)
Equillium registers Phase 1 trial of EQ504 for ulcerative colitis
Regeneron registers Phase 1b hemodialysis study, Phase 1 Graves' disease trial
Atrium Therapeutics amends 8-K to fix share count after PIPE offering
Thursday, October 8
FDA approves new Breztri Aerosphere application from AstraZeneca
The FDA approved a Type 5 new formulation or manufacturer submission for Breztri Aerosphere on October 8, 2026.
Drugs@FDA
MD Anderson's phase 2 trial of subcutaneous blinatumomab in MRD-positive B-ALL listed as suspended
The single-site study, sponsored by MD Anderson with Amgen as collaborator, was suspended at the principal investigator's request, per a clinicaltrials.gov update posted October 8, 2026.
ClinicalTrials.gov
FDA approves Teva's Weltruza, an extended release injectable olanzapine
The agency cleared the new application on October 8, 2026, covering three dosage strengths for the antipsychotic formulation.
Drugs@FDA
FDA approves supplement 65 for Genentech's Tecentriq
The agency cleared an efficacy supplement for the atezolizumab injection under priority review, with a status date of October 8, 2026.
Drugs@FDA
Avutometinib-defactinib trial in mesonephric gynecologic cancer stays active, not recruiting
Aardvark Therapeutics adds biostatistics veteran David Zhang to board
Aardvark named David Zhang, who led biometrics work behind CAMZYOS and Abivax's ulcerative colitis trials, as an independent director effective October 7, 2026.
SEC filing
X4 Pharmaceuticals secures up to $150 million debt facility with K2 HealthVentures
The new loan replaces X4's prior Hercules facility and is intended to help fund mavorixafor's potential commercial launch in chronic neutropenia.
SEC filing